drugset / Trial / NCT02019355
Actinic Keratosis Study
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to determine the effectiveness of a new combination therapy for actinic keratosis. This study investigates a new indication for an FDA-approved topical medication, calcipotriol, for treatment of actinic keratosis, including how well it works and how safe it is when used in combination with the standard of care medication (5-fluorouracil) for the skin condition.
Timeline
- Start
- 2013-10
- Primary completion
- 2015-03
- Completion
- 2015-03
Outcome
Met primary endpoint
paper Calcipotriol plus 5-FU versus Vaseline plus 5-FU led to an 87.8% versus 26.3% mean reduction in the number of actinic keratoses in participants (P < 0.0001 PMID 27869649 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcipotriol | Small molecule | 0.005 % | Topical |
| Background | fluorouracil | Small molecule | 5 % | Topical |